Category: Judicial

340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.

On Monday, the justices heard the case of

Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.

Arguments in American Hospital Association v. Becerra are due

Drug manufacturer Novo Nordisk late yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi filed its appeal earlier yesterday.

Novo Nordisk’s notice of appeal, like Sanofi’s, is

Drug manufacturer Sanofi today gave notice that it is appealing a federal district judge’s Nov. 5 orders and opinions in its 340B contract pharmacy lawsuit.

Sanofi’s one-sentence Nov. 19 notification to the federal government defendants and U.S. Chief District

Drug manufacturer Lilly’s appeal of a federal district judge’s ruling late last month in the company’s 340B contract pharmacy lawsuit has hit a procedural snag.

In an unsigned pair of orders on Tuesday, the federal appeals court in Chicago questioned

Drug manufacturer’s AstraZeneca and the federal government continue to joust in court as they await a crucial decision in the company’s 340B contract pharmacy lawsuit.

The two sides on Friday filed a joint status report in Astra’s lawsuit to

U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

In a Nov. 11 joint

Drug manufacturer Eli Lilly late yesterday filed notice that it is appealing a federal district judge’s Oct. 29 ruling partially in Lilly’s favor and partially for the federal government on the legality of Lilly’s denials of 340B ceiling prices when

The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next